Sablich Kim
EVP, GM of U.S., Commercial Ma at JAZZ; Chief Commercial Officer at Myovant Sciences Ltd.
- Sold, on record
- $1.5M
- Dollars the filings state
- Form 4 sales
- 6
- Latest Mar 8, 2023
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- JAZZJazz Pharmaceuticals plcEVP, GM of U.S., Commercial Ma
- Myovant Sciences Ltd.Chief Commercial Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- JAZZ9,590 shares
- Myovant Sciences Ltd.8,210 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale Myovant Sciences Ltd.Plan not statedDec 18, 2019 2019
Sold 2,585 shares at $16.22 ($42k)
Sablich Kim, Chief Commercial Officer
Sold 3.9% of holdings ($1.1M position)64,530 shares leftFirst sale on recordFiling
- 2 Form 4 sale Myovant Sciences Ltd.Plan not statedJan 15, 2020 +28 days
Sold 4,840 shares at $14.04 ($68k)
Sablich Kim, Chief Commercial Officer
Sold 7.5% of holdings ($906k position)59,690 shares leftFiling
- 3 Form 4 sale Myovant Sciences Ltd.Plan not statedMar 18, 2020 +63 days
Sold 785 shares at $7.37 ($6k)
Sablich Kim, Chief Commercial Officer
Sold 1.3% of holdings ($440k position)58,905 shares leftFiling
- 4 Form 4 sale JAZZPlan not statedNov 11, 2021 +603 days
Sold 2,748 shares at $135.01 ($371k)
Sablich Kim, EVP & GM, North America
Sold 11.5% of holdings ($3.2M position)21,135 shares leftFirst sale on recordFiling
- 5 Form 4 sale JAZZPlan not statedJun 7, 2022 +208 days
Sold 3,829 shares at $151.45 ($580k)
Sablich Kim, EVP & GM, North America
Sold 13.4% of holdings ($4.3M position)24,754 shares leftFiling
- 6 Form 4 sale JAZZPlan not statedMar 8, 2023 +274 days
Sold 3,013 shares at $139.74 ($421k)
Sablich Kim, EVP, GM of U.S., Commercial Ma
Sold 9% of holdings ($4.7M position)30,560 shares leftFiling
Every transaction
Loading transactions…
Sales and notices (6)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mar 8, 2023 | Mar 10, 2023 | JAZZ | EVP, GM of U.S., Commercial Ma | Form 4 sale | 3,013 | $421k | 9.0% | Plan not stated | SEC |
| Jun 7, 2022 | Jun 8, 2022 | JAZZ | EVP & GM, North America | Form 4 sale | 3,829 | $580k | 13.4% | Plan not stated | SEC |
| Nov 11, 2021 | Nov 15, 2021 | JAZZ | EVP & GM, North America | Form 4 sale | 2,748 | $371k | 11.5% | Plan not stated | SEC |
| Mar 18, 2020 | Mar 19, 2020 | Myovant Sciences Ltd. | Chief Commercial Officer | Form 4 sale | 785 | $6k | 1.3% | Plan not stated | SEC |
| Jan 15, 2020 | Jan 16, 2020 | Myovant Sciences Ltd. | Chief Commercial Officer | Form 4 sale | 4,840 | $68k | 7.5% | Plan not stated | SEC |
| Dec 18, 2019 | Dec 19, 2019 | Myovant Sciences Ltd. | Chief Commercial Officer | Form 4 sale | 2,585 | $42k | 3.9% | Plan not stated | SEC |